The Corona(COVID-19) (SARS-CoV-2) Cure using Blood Transfusion and Machine Learning

References

[1] Tirado SM, Yoon KJ. Antibody-dependent enhancement of virus infection and disease. Viral Immunol. 2003; 16:69–86. [PubMed] [Google Scholar]

[2] Wang SF, Tseng SP, Yen CH, et al. Antibody-dependent SARS coronavirus infection is mediated by antibodies against spike proteins. Biochem Biophys Res Commun. 2014; 451:208–14. [PMC free article] [PubMed] [Google Scholar]

[3] Halstead SB. Dengue antibody-dependent enhancement: knowns and unknowns. Microbiol Spectr. 2014; 2 AID-0022-2014. [PubMed] [Google Scholar]

[4] Olsen CW, Corapi WV, Ngichabe CK, et al. Monoclonal antibodies to the spike protein of feline infectious peritonitis virus mediate antibody-dependent enhancement of infection of feline macrophages. J Virol. 1992; 66:956–65. [PMC free article] [PubMed] [Google Scholar]

[5] Guzman MG, Alvarez M, Halstead SB. Secondary infection as a risk factor for dengue hemorrhagic fever/dengue shock syndrome: a historical perspective and role of antibody-dependent enhancement of infection. Arch Virol. 2013; 158:1445–59. [PubMed] [Google Scholar]

[6] Ubol S, Halstead SB. How innate immune mechanisms contribute to antibody-enhanced viral infections. Clin Vaccine Immunol. 2010; 17:1829–35. [PMC free article] [PubMed] [Google Scholar]

[7] Colebunders RL, Cannon RO. Large-scale convalescent blood and plasma transfusion therapy for Ebola virus disease. J Infect Dis. 2015; 211:1208–10. [PubMed] [Google Scholar]

[8] Liumbruno GM, Franchini M. Solvent/detergent plasma: pharmaceutical characteristics and clinical experience. J Thromb Thrombolysis. 2015; 39:118–28. [PMC free article] [PubMed] [Google Scholar]

[9] Picker SM. Current methods for the reduction of blood-borne pathogens: a comprehensive literature review. Blood Transfus. 2013; 11:343–8. [PMC free article] [PubMed] [Google Scholar]

[10] The New York Times. How many Ebola patients have been treated outside of Africa? [Accessed on 21/05/2015]. Updated Jan. 26, 2015 Available at http://www.nytimes.com/interactive/2014/07/31/world/africa/ebola-virus-outbreak-qa.html?_r=0.

[11] European Blood Alliance. Newsletter 2015-1. [Accessed on 21/05/2015]. Available at: http://www.sweba.se/sites/default/files/EBA%20Newsletter%202015_1.pdf.

[12] European Centre for Disease Prevention and Control. Overview of Ebola research – March 2015 ECDC. Treatment and vaccine development. [Accessed on 21/05/2015]. Last updated 5 March 2015 Available at http://ecdc.europa.eu/en/healthtopics/ebola_marburg_fevers/Pages/treatment-vaccines.aspx.

[13] World Health Organization. Essential medicines and health products. [Accessed on 21/05/2015]. Available at: http://www.who.int/medicines/ebola-treatment/emp_ebola_therapies/en/

[14] World Health Organization. Community engagement and education, recruitment, and retention of people recovered from Ebola as potential donors for convalescent whole blood and plasma. Interim guidance for National Health Authorities, Blood Transfusion Services, and researchers. Apr 2015. [Accessed on 21/05/2015]. Available at: http://www.who.int/bloodsafety/interim-guidance_CWB-CP.pdf.

[15] Gulland A. First Ebola treatment is approved by WHO. Br Med J. 2014; 349:5539. [PubMed] [Google Scholar]

[16] Cohen J. Ebola vaccine: little and late. Science. 2014; 345:1441–42. [PubMed] [Google Scholar]

[17] Qiu X, Audet J, Wong G, et al. Successful treatment of ebola virus-infected cynomolgus macaques with monoclonal antibodies. Sci Transl Med. 2012; 4:138ra81. [PubMed] [Google Scholar]

[18] Olinger GG, Pettitt J, Kim D, et al. Delayed treatment of Ebola virus infection with plant-derived monoclonal antibodies protect rhesus macaques. Proc Natl Acad Sci USA. 2012; 109:18030–5. [PMC free article] [PubMed] [Google Scholar]

[19] Dye JM, Herbert AS, Kuehne AI, et al. Postexposure antibody prophylaxis protects nonhuman primates from filovirus disease. PNAS. 2012;13:5034–9. [PMC free article] [PubMed] [Google Scholar]

[20] Mapa K, Massamba M, Kibadi K, et al. Treatment of Ebola hemorrhagic fever with blood transfusions from convalescent patients. International Scientific and Technical Committee. J Infect Dis. 1999;179:S18–23. [PubMed] [Google Scholar]

[21] Kudoyarova-Zubavichene NM, Sergeyev NN, Chepurnov AA, Netesov SV. Preparation and use of hyperimmune serum for prophylaxis and therapy of Ebola virus infections. J Infect Dis. 1999;179:S218–23. [PubMed] [Google Scholar]

[22] Jahrling PB, Geisbert J, Swearengen JR, et al. Passive immunization of Ebola virus-infected cynomolgus monkeys with immunoglobulin from hyperimmune horses. Arch Virol Suppl. 1996;11:135–40. [PubMed] [Google Scholar]

[23] Ruggiero HA, Pérez Izquierdo F, Milani HA, et al. [Treatment of Argentine hemorrhagic fever with convalescent's plasma. 4433 cases]. Presse Med. 1986;15:2239–42. [In French.] [PubMed] [Google Scholar]

[24] Enria DA, Maiztegui JI. Antiviral treatment of Argentine hemorrhagic fever. Antivir Res. 1994;23:23–31. [PubMed] [Google Scholar]

[25] Enria DA, Briggiler AM, Fernández NJ, et al. Importance of dose of neutralizing antibodies in the treatment of Argentine hemorrhagic fever with immune plasma. Lancet. 1984;2:255–6. [PubMed] [Google Scholar]

[26] World Health Organization. Experimental therapies: growing interest in the use of whole blood or plasma from recovered Ebola patients (convalescent therapies) Ebola situation assessment - 26 September 2014. [Accessed on 21/05/2015]. Available at: http://www.who.int/mediacentre/news/ebola/26-september-2014/en/

[27] Mair-Jenkins J, Saavedra-Campos M, Baillie JK, et al. Convalescent Plasma Study Group. The effectiveness of convalescent plasma and hyperimmune immunoglobulin for the treatment of severe acute respiratory infections of viral etiology: a systematic review and exploratory meta-analysis. J Infect Dis. 2015;211:80–90. [PMC free article] [PubMed] [Google Scholar]

[28] Jahrling PB, Frame JD, Rhoderick JB, Monson MH. Endemic Lassa fever in Liberia. Selection of optimally effective plasma for treatment by passive immunization. Trans R Soc Trop Med Hyg. 1985;79:380–4. [PubMed] [Google Scholar]

[29] Mozdzanowska K, Furchner M, Washko G, et al. A pulmonary influenza virus infection in SCID mice can be cured by treatment with hemagglutinin-specific antibodies that display very low virus-neutralizing activity in vitro. J Virol. 1997;71:4347–55. [PMC free article] [PubMed] [Google Scholar]

[30] Hui DS, Lee N. Adjunctive therapies and immunomodulating agents for severe influenza. Influenza Other Respir Viruses. 2013;7(Suppl 3):52–9. [PMC free article] [PubMed] [Google Scholar]

[31] Leider JP, Brunker PA, Ness PM. Convalescent transfusion for pandemic influenza: preparing blood banks for a new plasma product? Transfusion. 2010;50:1384–98. [PubMed] [Google Scholar]

[32] Kong LK, Zhou BP. Successful treatment of avian influenza with convalescent plasma. Hong Kong Med J. 2006;12:489. [PubMed] [Google Scholar]

[33] Young MK, Nimmo GR, Cripps AW, Jones MA. Post-exposure passive immunization for preventing measles. Cochrane Database Syst Rev. 2014;4:CD010056. [PubMed] [Google Scholar]

[34] World Health Organization Mers-Cov Research Group. State of knowledge and data gaps of Middle East Respiratory Syndrome Coronavirus (MERS-CoV) in humans. PLoS Curr. 2013;12:5. [PMC free article] [PubMed] [Google Scholar]

[35] Hemming VG. Use of intravenous immunoglobulins for prophylaxis or treatment of infectious diseases. Clin Diagn Lab Immunol. 2001;8:859–63. [PMC free article] [PubMed] [Google Scholar]

[36] Lesne E, Brodin P, Saint-Girons F. Plasma therapy in influenza. Presse Med. 1919;27:181–2. [Google Scholar]

[37] Miller OO, McConnell WT. Report of influenza treated with serum from recovered cases. Ky Med J. 1919;17:218–9. [Google Scholar]

[38] Jacobaeus Treatment of influenza pneumonia with serum from convalescents. Svenska Lakartidnin. 1920;18:385–99. [Google Scholar]

[39] Francis FD, Hall MW, Gaines AR. Early use of convalescent serum in influenza. Mil Surg. 1920;47:177–9. [Google Scholar]

[40] Behring E, Kitasato S. Ueber das Zustandekommen der Diphtherie-Immunitat und der Tetanus-Immunitat bei thieren. Deutsche medizinsche Wochenschrift. 1890;16:1113–4. [Google Scholar]Brock TD, editor. Milestones in Microbiology: 1556 to 1940. Washington: ASM Press; 1998. p. 138. [Google Scholar]

[41] Marano G, Vaglio S, Pupella S, et al. Convalescent plasma: new evidence for an old therapeutic tool?. Blood Transfus. 2016;14(2):152‐157. doi:10.2450/2015.0131-15

[42] World Health Organization. Interim guidance for national health authorities and blood transfusion services. Geneva: World Health Organization; Sep 2014. [Accessed on 21/05/2015]. Use of convalescent whole blood or plasma collected from patients recovered from Ebola virus disease for transfusion, as an empirical treatment during outbreaks. Available at: http://apps.who.int/iris/bitstream/10665/135591/1/WHO_HIS_SDS_2014.8_eng.pdf?ua=1. [Google Scholar]

[43] Dodd RY. Emerging pathogens and their implications for the blood supply and transfusion transmitted infections. Br J Haematol. 2012;159:135–42. [PMC free article] [PubMed] [Google Scholar]

[44] Burnouf T, Seghatchian J. Ebola virus convalescent blood products: where we are now and where we may need to go. Transfus Apher Sci. 2014;51:120–5. [PMC free article] [PubMed] [Google Scholar]

[45] Keller MA, Stiehm ER. Passive immunity in prevention and treatment of infectious diseases. Clin Microbiol Rev. 2000;13:602–14. [PMC free article] [PubMed] [Google Scholar]

[46] Roback JD, Guarner J. Convalescent Plasma to Treat COVID-19: Possibilities and Challenges. JAMA. 2020;323(16):1561–1562. DOI:10.1001/jama.2020.4940.

@article{1702290,
      author = {Asim Sayyed},
      title = {The Corona(COVID-19) (SARS-CoV-2) Cure using Blood Transfusion and Machine Learning},
      journal = {Iconic Research And Engineering Journals},
      year = {2020},
      volume = {3},
      number = {11},
      pages = {64-72},
      issn = {2456-8880},
      url = {https://www.irejournals.com/formatedpaper/1702290.pdf},
      abstract = {(SARS-CoV-2; previously provisionally been named 2019 novel coronavirus or 2019-nCoV) disease (COVID-19) in China at the tip of 2019 had caused an outsized global outbreak and it is a significant public health issue. As of 6th May 2020, data from the World Health Organization (WHO) have shown that quite 3.4 Million cases out of which 1.27 M somehow manages to recover whereas 265k is unfortunately dead which is identified in 28 countries/regions. On 30th January 2020, WHO declared COVID-19 the sixth public health emergency of international concern. It's spread by human-to-human transmission via droplets or direct contact, and infection has been estimated to possess a mean period of 6.4 days, and a basic reproduction number of two. Among patients with pneumonia caused by SARS-CoV-2 (novel coronavirus pneumonia or Wuhan pneumonia), fever was the foremost common symptom, followed by a cough. Bilateral lung involvement with ground-glass opacity was the foremost common finding from CAT images of the chest. The one case of SARS-CoV-2 pneumonia within the USA is responding well to redeliver, which is now undergoing a test in China. Currently, controlling infection to prevent the spread of SARS-CoV-2 is the first intervention getting used. However, public health authorities should keep monitoring true closely, because the more we are visiting to study this novel virus, and its associated outbreak. The purpose of this study is to put forth a theory about how blood transfusion from a corona recovered patient to a normal person could help the normal person to be immune to the virus. This treatment can also be termed as passive immunization as of PMC paper on blood transfusion in paragraph 1.},
      month = {May},
  }